US Renal Data System 2020 Annual Data Report: Epidemiology of Kidney Disease in the United States

Kirsten Johansen, Glenn M. Chertow, Rob Foley, David T. Gilbertson, Charles A. Herzog, Areef Ishani, Ajay K. Israni, Elaine Ku, Manjula Kurella Tamura, Shuling Li, Suying Li, Jiannong Liu, Gregorio T. Obrador, Ann M. O'Hare, Yi Peng, Neil R. Powe, Nicholas S. Roetker, Wendy L. St. Peter, Kevin C. Abbott, Kevin E. ChanIvonne H. Schulman, Jon Snyder, Craig Solid, Eric D. Weinhandl, Wolfgang C. Winkelmayer, James B. Wetmore

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish (US)
Pages (from-to)A7-A8
JournalAmerican Journal of Kidney Diseases
Issue number4
StatePublished - Apr 2021

Bibliographical note

Funding Information:
The US Renal Data System (USRDS) Annual Data Report (ADR) is an authoritative source of data about the chronic kidney disease (CKD) and kidney failure populations in the United States. Herein, we will refer to the latter using the Centers for Medicare & Medicaid Services (CMS) term, end-stage renal disease (ESRD). Supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health and the CMS, the USRDS Coordinating Center is operated by the Chronic Disease Research Group within the Hennepin Healthcare Research Institute in Minneapolis, Minnesota.

Funding Information:
Funding for the USRDS Coordinating Center is provided under contract to Hennepin Healthcare Research Institute ( 75N94019C00006 ).

Funding Information:
Dr Johansen reports personal fees from GSK and American Society of Nephrology (ASN). Dr Chertow reports personal fees from Satellite Healthcare, Akebia, Amgen, Ardelyx, AstraZeneca, Baxter, Cricket, DiaMedica, Gilead, Reata, Sanifit, Vertex, Angion, Bayer, and ReCor; additionally, he reports serving on advisory boards for Ardelyx, CloudCath, Durect, and Outset. Dr Foley reports personal fees from Novartis, FibroGen, and AstraZeneca. Dr Gilbertson received consulting income from Amgen. Dr Herzog reports grants and/or personal fees from National Heart Lung and Blood Institute (NHLBI/NIH), NIH/NIDDK, Abbvie, Amgen, AstraZeneca, Corvidia, Diamedica, FibroGen, Janssen, NxStage, Pfizer, Relypsa, Sanifit, University of Oxford, Bristol-Myers Squibb, University of British Columbia, UpToDate, Bayer, and Johnson & Johnson. Dr Israni reports participatation on an advisory board for CSL Behring. Dr Ku reports grant support from Care DX, personal fees from Tricida, and advisory board participation for Reata. Dr Obrador reports grant funding from Rio Arronte Foundation and Secretariat of Education, Science, Technology and Innovation of Mexico City; advisory board participation for Johnson & Johnson’s CREDENCE trial, GlaxoSmithKline’s ASCEND trial, Gilead's MOSAIC trial, GlaxoSmithKline, Vifor, and Roche Mexico; speaker fees/honoraria from AstraZeneca, Amgen Mexico, Seminars in Nephrology, and AbbVie Mexico; and royalties from Elsevier Barcelon and UpToDate. Dr O’Hare reports personal fees from Chugai, UpToDate, Fondation D.E.V.E.N.I.R., ASN, Hammersmith Hospital, and travel fees from Health and Aging Policy Program. Dr St. Peter reports serving on advisory boards for Kidney Health Initiative and National Kidney Foundation, and personal fees from Quality Insights, OptumLabs, and Total Renal Care, Inc. (DaVita). Dr Snyder reports research funding from CSL Behring, Atara Biotherapeutics, Bristol-Myers Squibb, and Astellas; membership in the Board of Directors for Donate Life America and Organ Donation and Transplantation Alliance; and membership in the Medical Policy Board at LifeSource Upper Midwest Organ Procurement Organization. Dr Weinhandl was employed by NxStage Medical and Fresenius Medical Care North America, and reports a consulting relationship with Fresenius Medical Care North America. Dr Winkelmayer reports personal fees from Akebia, AstraZeneca, Bayer, Daichii-Sankyo, Janssen, Otsuka, Reata, Relypsa, and Vifor FMC Renal Pharma. Dr Wetmore reports personal fees from Reata and Rockwell Medical. The remaining authors declare that they have no relevant financial interests.

PubMed: MeSH publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

Cite this